{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T16:01:32Z","timestamp":1790438492326,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Government of India Department of Biotechnology","doi-asserted-by":"publisher","award":["BT\/PR45270\/MED\/30\/2418\/2022"],"award-info":[{"award-number":["BT\/PR45270\/MED\/30\/2418\/2022"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.intimp.2026.117317","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T19:33:27Z","timestamp":1788377607000},"page":"117317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Chimeric IL-15 as a next-generation immunotherapeutic: preclinical assessment of efficacy and safety"],"prefix":"10.1016","volume":"188","author":[{"given":"Himali","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansi","family":"Ahuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyur","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandini","family":"Ahuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeet","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Digna","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shital","family":"Panchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarthi","family":"Sundararajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarat K.","family":"Dalai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2026.117317_bb0005","doi-asserted-by":"crossref","DOI":"10.3892\/etm.2021.10107","article-title":"Therapeutic potential of interleukin-15 in cancer (review)","volume":"22","author":"Isvoranu","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.intimp.2026.117317_bb0010","first-page":"9","article-title":"Principles of immunotherapy: implications for treatment strategies in Cancer and infectious diseases","author":"Naran","year":"2018","journal-title":"Front. Microbiol."},{"issue":"4","key":"10.1016\/j.intimp.2026.117317_bb0015","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s41423-020-00530-6","article-title":"Human immunology and immunotherapy: main achievements and challenges","volume":"18","author":"Varad\u00e9","year":"2021","journal-title":"Cell. Mol. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2026.117317_bb0020","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.4049\/jimmunol.170.10.5018","article-title":"IL-15 promotes the survival of naive and memory phenotype CD8+ T cells","volume":"170","author":"Berard","year":"2003","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117317_bb0025","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1146\/annurev.immunol.24.021605.090727","article-title":"Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis","volume":"24","author":"Ma","year":"2006","journal-title":"Annu. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2026.117317_bb0030","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1359-6101(01)00021-1","article-title":"Interleukin-2 and interleukin-15: immunotherapy for cancer","volume":"13","author":"Fehniger","year":"2002","journal-title":"Cytokine Growth Factor Rev."},{"issue":"8","key":"10.1016\/j.intimp.2026.117317_bb0035","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/nri1901","article-title":"The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design","volume":"6","author":"Waldmann","year":"2006","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2026.117317_bb0040","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1074\/jbc.M705725200","article-title":"Intracellular interaction of Interleukin-15 with its receptor \u03b1 during production leads to mutual stabilization and increased bioactivity","volume":"283","author":"Bergamaschi","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.intimp.2026.117317_bb0045","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1084\/jem.20082013","article-title":"IL-15 trans-presentation promotes human NK cell development and differentiation in vivo","volume":"206","author":"Huntington","year":"2009","journal-title":"J. Exp. Med."},{"issue":"7","key":"10.1016\/j.intimp.2026.117317_bb0050","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1182\/blood-2005-01-0064","article-title":"Membrane-bound and soluble IL-15\/IL-15R\u03b1 complexes display differential signaling and functions on human hematopoietic progenitors","volume":"106","author":"Giron-Michel","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.intimp.2026.117317_bb0055","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1158\/2326-6066.CIR-15-0009","article-title":"The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy","volume":"3","author":"Waldmann","year":"2015","journal-title":"Cancer Immunol. Res."},{"issue":"11","key":"10.1016\/j.intimp.2026.117317_bb0060","doi-asserted-by":"crossref","DOI":"10.4161\/onci.26442","article-title":"The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8+ T cells into innate-like effector cells with antitumor activity","volume":"2","author":"Wong","year":"2013","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.intimp.2026.117317_bb0065","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/ijc.29686","article-title":"Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model","volume":"138","author":"Mathios","year":"2016","journal-title":"Int. J. Cancer"},{"issue":"10","key":"10.1016\/j.intimp.2026.117317_bb0070","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1158\/0008-5472.CAN-12-2357","article-title":"Efficacy and mechanism-of-action of a novel Superagonist Interleukin-15: Interleukin-15 receptor \u03b1Su\/fc fusion complex in syngeneic murine models of multiple myeloma","volume":"73","author":"Xu","year":"2013","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.intimp.2026.117317_bb0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096705","article-title":"Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder Cancer rat model; a role for cytokine production and NK cell expansion","volume":"9","author":"Gomes-Giacoia","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.intimp.2026.117317_bb0080","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1158\/2326-6066.CIR-15-0093-T","article-title":"Comparison of the superagonist complex, ALT-803, to IL15 as cancer immunotherapeutics in animal models","volume":"4","author":"Rhode","year":"2016","journal-title":"Cancer Immunol. Res."},{"issue":"19","key":"10.1016\/j.intimp.2026.117317_bb0085","doi-asserted-by":"crossref","DOI":"10.1172\/JCI144365","article-title":"NKTR-255 is a polymer-conjugated IL-15 with unique mechanisms of action on T and natural killer cells","volume":"131","author":"Robinson","year":"2021","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.intimp.2026.117317_bb0090","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002024","article-title":"NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy","volume":"9","author":"Miyazaki","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.intimp.2026.117317_bb0095","article-title":"Nanrilkefusp alfa (SOT101), an IL-15 receptor \u03b2\u03b3 superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers","volume":"6","author":"Champiat","year":"2025","journal-title":"Cell Rep Med."},{"key":"10.1016\/j.intimp.2026.117317_bb0100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.646159","article-title":"Development of stable chimeric IL-15 for trans-presentation by the antigen presenting cells","volume":"12","author":"Patidar","year":"2021","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2026.117317_bb0105","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1158\/1078-0432.CCR-17-2451","article-title":"A first-in-human phase I study of subcutaneous outpatient recombinant human IL15 (rhIL15) in adults with advanced solid tumors","volume":"24","author":"Miller","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"22","key":"10.1016\/j.intimp.2026.117317_bb0110","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.1158\/1078-0432.CCR-18-0945","article-title":"Phase I trial of ALT-803, a novel recombinant IL15 complex, in patients with advanced solid tumors","volume":"24","author":"Margolin","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.intimp.2026.117317_bb0115","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","article-title":"Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer","volume":"33","author":"Conlon","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.intimp.2026.117317_bb0120","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1182\/blood-2017-12-823757","article-title":"First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation","volume":"131","author":"Romee","year":"2018","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.intimp.2026.117317_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23137311","article-title":"Interleukin 15 in cell-based cancer immunotherapy","volume":"23","author":"Zhou","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.intimp.2026.117317_bb0130","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.4049\/jimmunol.2100066","article-title":"Phase I trial characterizing the pharmacokinetic profile of N-803, a chimeric IL-15 superagonist, in healthy volunteers","volume":"208","author":"Rubinstein","year":"2022","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.intimp.2026.117317_bb0135","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2026.117317_bb0140","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/07388551.2013.834293","article-title":"Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics","volume":"35","author":"Rath","year":"2015","journal-title":"Crit. Rev. Biotechnol."},{"issue":"11","key":"10.1016\/j.intimp.2026.117317_bb0145","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.molmed.2025.05.014","article-title":"IL-15 in CAR engineering: striking an efficacy\u2013safety balance","volume":"31","author":"Li","year":"2025","journal-title":"Trends Mol. Med."},{"issue":"1","key":"10.1016\/j.intimp.2026.117317_bb0150","doi-asserted-by":"crossref","DOI":"10.4110\/in.2024.24.e11","article-title":"IL-15 in T-cell responses and immunopathogenesis","volume":"24","author":"Lee","year":"2024","journal-title":"Immune Netw."},{"key":"10.1016\/j.intimp.2026.117317_bb0155","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1117092","article-title":"IL-15 promotes self-renewal of progenitor exhausted CD8 T cells during persistent antigenic stimulation","volume":"14","author":"Lee","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2026.117317_bb0160","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/s12951-022-01648-7","article-title":"In vivo fluorescence imaging: success in preclinical imaging paves the way for clinical applications","volume":"20","author":"Refaat","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.intimp.2026.117317_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01813","article-title":"Interleukin 15 pharmacokinetics and consumption by a dynamic cytokine sink","volume":"11","author":"Hangasky","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117317_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107318","article-title":"Biological effects of IL-15 on immune cells and its potential for the treatment of cancer","volume":"91","author":"Zhang","year":"2021","journal-title":"Int. Immunopharmacol."},{"issue":"10","key":"10.1016\/j.intimp.2026.117317_bb0175","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1016\/j.ymthe.2021.06.001","article-title":"Bifunctional TGF-\u03b2 trap\/IL-15 protein complex elicits potent NK cell and CD8+ T cell immunity against solid tumors","volume":"29","author":"Liu","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.intimp.2026.117317_bb0180","doi-asserted-by":"crossref","first-page":"868","DOI":"10.3389\/fimmu.2020.00868","article-title":"IL-15 in the combination immunotherapy of cancer","volume":"11","author":"Waldmann","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.117317_bb0185","article-title":"Advances in IL\u201315\u2013based cancer immunotherapy and divergent immunological effects of IL\u20132 and IL\u201315 signaling via the shared IL\u20132R\u03b2\u03b3 receptor","volume":"17","author":"Gao","year":"2026","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2026.117317_bb0190","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41587-024-02226-y","article-title":"Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method","volume":"43","author":"Li","year":"2025","journal-title":"Nat. Biotechnol."},{"issue":"10","key":"10.1016\/j.intimp.2026.117317_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100804","article-title":"Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells","volume":"6","author":"Li","year":"2025","journal-title":"Med"},{"issue":"3","key":"10.1016\/j.intimp.2026.117317_bb0200","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/imm.12784","article-title":"Adoptive transfer of murine T cells expressing a chimeric-PD 1-Dap10 receptor as an immunotherapy for lymphoma","volume":"152","author":"Lynch","year":"2017","journal-title":"Immunology"},{"key":"10.1016\/j.intimp.2026.117317_bb0205","series-title":"Melanoma: Methods and Protocols","first-page":"645","article-title":"Generation of murine chimeric antigen receptor T cells for adoptive T cell therapy for melanoma","author":"Barber","year":"2021"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926011641?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576926011641?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:43:11Z","timestamp":1790437391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576926011641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":41,"alternative-id":["S1567576926011641"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117317","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric IL-15 as a next-generation immunotherapeutic: preclinical assessment of efficacy and safety","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.117317","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117317"}}